12:00 AM
Nov 12, 2012
 |  BioCentury  |  Finance

Betting on biosimilars

Bio-banker joins Coherus to build on top of Daiichi biosimilars deal
Betting on biosimilars

George Montgomery joined biosimilars company Coherus Biosciences Inc. as CFO after having spent much of the last 25 years in San Francisco's financial district.

Coherus came out of stealth mode in May when it announced a partnership with Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) to develop and commercialize biosimilars of autoimmune drugs etanercept and rituximab in Asia.

Coherus' three other programs are under wraps, though oncology and inflammation are the focus. The company plans...

Read the full 365 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >